UNSPSC 51362701: Lirequinil

This classification denotes a sedative and hypnotic with the molecular formula C26H25ClN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2VUW1087AD, chemically known as (3s)-1-((10-chloro-6,7-dihydro-4-oxo-3-phenyl-4h-benzo(a)quinolizin-1-yl)carbonyl)-3-ethoxypyrrolidine. but generally known as lirequinil, which bears US NIH Compound Identifier 3045375. European Medicines Agency schedules Lirequinil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08529MIG.

UNSPSC 51362701 Lirequinil, a Commodity code, encompasses pharmaceutical products that state and local health agencies procure to support community health and pharmacy benefit programs. The recent opportunities reveal that state and local governments are actively purchasing pharmaceuticals through multiple channels: direct procurement of specific health interventions (naloxone and drug deactivation systems), exploratory contracting for direct-to-manufacturer prescription programs to bypass traditional pharmacy benefit managers, and participation in cooperative purchasing alliances for generic multi-source pharmaceuticals and over-the-counter products distributed through authorized wholesalers. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing organizations. Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the mix of jurisdictions and administrative structures pursuing these acquisitions.

Recent activity spans Florida, Texas, and a multistate consortium including Minnesota and Oregon. Seminole County released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response deadline July 26, 2023. The Texas HHS Commission posted RFI HHS0017013 on April 3, 2026, requesting vendor information on direct-to-manufacturer prescription capabilities as a preliminary market intelligence phase prior to a formal RFP. MMCAP posted RFP S1070000015802 on January 20, 2026, closing March 26, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson) with awards effective July 1, 2026, and evaluation weighted 75 percent on price competitiveness. All three opportunities require vendor compliance with federal and state regulations, including FDA requirements, drug supply chain security standards, and E-Verify employment verification.